Roche Colombia, led by its General Manager Marieli Alfonzo, has announced a substantial investment of US$240 million over the next five years, as part of its strategy to further consolidate its position in the local market.
This initiative is part of the expansion plan that began with the opening of a new distribution center on the outskirts of Bogotá, with an initial investment of US$40 million in 2023.
In the last year, Roche's active presence in Colombia resulted in 731,000 treatments and 168 million diagnostic tests, distributed across 1,200 service points, including laboratories, hospitals, and blood banks.
The pharmaceutical company operates in various medical areas, ranging from oncology to rare diseases, ophthalmology, and neurology, establishing itself as a key player in the Colombian health sector.
Marieli Alfonzo emphasized the strategic importance of Colombia for Roche, highlighting it as one of the three most relevant countries in Latin America, considering the population and the structure of the health system.
In this context, the projected investment not only seeks to strengthen Roche's presence in the country, but is also expected to generate a positive impact on employment, increasing the staff from 470 to more than 550 employees.
In addition to growth in the number of employees, the investment aims to ensure high standards of quality, safety, and efficacy in the products and services offered by Roche.
Marieli Alfonzo concluded by expressing that this US$240 million investment represents the company's long-term commitment in Colombia, reaffirming its commitment to the country's present and future in the health sector.
With information from: La República.
Receive all industry news in our weekly newsletter Dialéctica Científica.